PE20080935A1 - THERAPY USING CYTOKINE INHIBITORS - Google Patents

THERAPY USING CYTOKINE INHIBITORS

Info

Publication number
PE20080935A1
PE20080935A1 PE2007000714A PE2007000714A PE20080935A1 PE 20080935 A1 PE20080935 A1 PE 20080935A1 PE 2007000714 A PE2007000714 A PE 2007000714A PE 2007000714 A PE2007000714 A PE 2007000714A PE 20080935 A1 PE20080935 A1 PE 20080935A1
Authority
PE
Peru
Prior art keywords
ter
tolil
butil
members
saturated
Prior art date
Application number
PE2007000714A
Other languages
Spanish (es)
Inventor
Constance A Crowley
Nancy G J Delaet
Justin Ernst
Carrie Gail Grove
Bonnie Hepburn
Bernard King
Christopher J Larson
Stephen Miller
Kent Pryor
Lewis J Shuster
Original Assignee
Kemia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kemia Inc filed Critical Kemia Inc
Publication of PE20080935A1 publication Critical patent/PE20080935A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN METODO PARA TRATAR UN TRASTORNO POR UNA O MAS CITOCINAS QUE COMPRENDE EN ADMINISTRAR UN COMPUESTO DE FORMULAS: IA, IB, IC, II, III y IV; ENTRE OTROS; SOLOS O EN COMBINACION; EN DONDE G ES UN CARBOCICLILO(C3-C10), HETEROCICLILO MONOCICLILO DE 5 A 8 MIEMBROS O HETEROCICLILO BICICLICO DE 8 A 11 MIEMBROS; X ES C(O), C(S) O CH2; Ar ES DIOXIDO DE INDAZOLILO, INDOLILO, IMIDAZOLILO, PIRAZOLILO, ENTRE OTROS; L ES UN ENLACE COVALENTE O UNA CADENA DE CARBONO(C1-C10) SATURADA O NO SATURADA; Q ES H, CICLOALQUILO, ARILO, ALCOXI DE C1-C6, ENTRE OTROS. SON SELECCIONADOS: (5-TER-BUTIL-2-p-TOLIL-2H-PIRAZOL-3-IL)-AMIDA DEL ACIDO 1H-INDAZOL-3-CARBOXILICO, 3-TER-BUTIL-5-FENIL-1-p-TOLIL-1,6-DIHIDRO-IMIDAZO[4,5-c]PIRAZOL, N-(5-TER-BUTIL-3-METANSULFONILAMINO-2-METOXI-FENIL)-2-[4-(2-MORFOLIN-4-IL-PIRIMIDIN-4-ILOXI)-NALTALEN-1-IL]-2-OXO-ACETAMIDA. TAMBIEN SE FERIERE A UNA COMPOSICION FARMACEUTICA. SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES, INFLAMATORIAS, CARDIOVASCULARES Y CANCERREFERS TO A METHOD TO TREAT A DISORDER DUE TO ONE OR MORE CYTOKINES THAT INCLUDES ADMINISTERING A COMPOUND OF FORMULAS: IA, IB, IC, II, III and IV; AMONG OTHERS; ALONE OR IN COMBINATION; WHERE G IS A CARBOCYCLYL (C3-C10), HETEROCYCLYL MONOCYCLYL OF 5 TO 8 MEMBERS OR BICYCLE HETEROCYCLE OF 8 TO 11 MEMBERS; X IS C (O), C (S) O CH2; Ar IS DIOXIDE OF INDAZOLYL, INDOLYL, IMIDAZOLYL, PYRAZOLIL, AMONG OTHERS; L IS A COVALENT LINK OR A SATURATED OR NON-SATURATED CARBON (C1-C10) CHAIN; Q IS H, CYCLOALKYL, ARYL, C1-C6 ALCOXY, AMONG OTHERS. THEY ARE SELECTED: (5-TER-BUTIL-2-p-TOLIL-2H-PIRAZOL-3-IL) -AMIDE OF 1H-INDAZOL-3-CARBOXYL ACID, 3-TER-BUTIL-5-FENIL-1-p- TOLIL-1,6-DIHYDRO-IMIDAZO [4,5-c] PYRAZOLE, N- (5-TER-BUTYL-3-METANSULPHONYLAMINO-2-METHYL-PHENYL) -2- [4- (2-MORFOLIN-4- IL-PYRIMIDIN-4-ILOXI) -NALTALEN-1-IL] -2-OXO-ACETAMIDE. IT ALSO CONFIRMS A PHARMACEUTICAL COMPOSITION. BEING USEFUL IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY, CARDIOVASCULAR AND CANCER DISEASES

PE2007000714A 2006-06-09 2007-06-08 THERAPY USING CYTOKINE INHIBITORS PE20080935A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81226806P 2006-06-09 2006-06-09
US83307806P 2006-07-24 2006-07-24
US83527006P 2006-08-03 2006-08-03

Publications (1)

Publication Number Publication Date
PE20080935A1 true PE20080935A1 (en) 2008-08-02

Family

ID=38832677

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000714A PE20080935A1 (en) 2006-06-09 2007-06-08 THERAPY USING CYTOKINE INHIBITORS

Country Status (8)

Country Link
EP (1) EP2035005A4 (en)
AR (1) AR061273A1 (en)
AU (1) AU2007257959A1 (en)
CA (1) CA2691214A1 (en)
CL (1) CL2007001670A1 (en)
PE (1) PE20080935A1 (en)
TW (1) TW200814998A (en)
WO (1) WO2007146712A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091106A2 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
AR063141A1 (en) 2006-10-04 2008-12-30 Pharmacopeia Inc DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION
CL2007002866A1 (en) 2006-10-04 2008-07-04 Pharmacopeia Inc COMPOUNDS DERIVED FROM 6-SUBSTITUTES-2- (BENCIMIDAZOLIL) PURINA AND PURINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASE, DISEASE MEDIATED BY M
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8440832B2 (en) * 2007-07-13 2013-05-14 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
CN101678107A (en) 2007-08-03 2010-03-24 萨米特公开有限公司 Drug combinations for the treatment of duchenne muscular dystrophy
JP5627574B2 (en) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド Compounds and methods for treating inflammatory and fibrotic diseases
CN102272120B (en) * 2008-11-07 2013-12-25 H.隆德贝克有限公司 Biologically active amides
EP2438059A1 (en) 2009-06-05 2012-04-11 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
US20110117055A1 (en) * 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
ES2548845T3 (en) * 2009-12-23 2015-10-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor and acetylsalicylic acid
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
MX2012012204A (en) 2010-04-22 2012-12-05 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds.
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088463A1 (en) 2011-10-21 2014-06-11 Abbvie Inc METHODS FOR HCV TREATMENT
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2527544T1 (en) 2011-10-21 2015-01-26 Abbvie Inc. Mono treatment (PSI-7977) or combination with ADF for use in the treatment of HCV
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
PT2968297T (en) 2013-03-15 2019-01-10 Verseon Corp Multisubstituted aromatic compounds as serine protease inhibitors
KR102373700B1 (en) 2014-04-02 2022-03-11 인터뮨, 인크. Anti-fibrotic pyridinones
ES2957761T3 (en) 2014-04-15 2024-01-25 Vertex Pharma Pharmaceutical compositions for the treatment of diseases mediated by the cystic fibrosis transmembrane conductance regulator
WO2016044662A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
AU2015360416A1 (en) 2014-12-10 2017-06-08 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
ES2931460T3 (en) 2015-02-27 2022-12-29 Verseon Int Corporation Substituted pyrazole compounds as serine protease inhibitors
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
HRP20221035T1 (en) 2015-11-19 2022-11-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US10011566B2 (en) 2015-12-15 2018-07-03 Astrazeneca Ab Compounds
PE20230731A1 (en) 2015-12-22 2023-05-03 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
KR20180107261A (en) 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 MAX binders as Myc modifiers and their uses
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
PE20190376A1 (en) * 2016-06-08 2019-03-08 Support Venture Gmbh PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
TWI771305B (en) 2016-06-20 2022-07-21 美商英塞特公司 Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
CN110177791B (en) 2016-12-20 2022-07-12 阿斯利康(瑞典)有限公司 Amino-triazolopyridine compounds and their use in the treatment of cancer
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
PE20200005A1 (en) 2016-12-22 2020-01-06 Incyte Corp DERIVATIVES OF TETRAHYDRO IMIDAZO [4,5-C] PYRIDINE AS INDUCTORS OF INTERNALIZATION PD-L1
ES2874756T3 (en) 2016-12-22 2021-11-05 Incyte Corp Triazolo [1,5-A] pyridine derivatives as immunomodulators
WO2018213140A1 (en) * 2017-05-15 2018-11-22 Zeno Royalties & Milestones, LLC Analgesic compounds
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN111646986B (en) * 2017-09-13 2022-03-25 厦门稀土材料研究所 Nicotinic acid derivative and preparation method and application thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
EP3728228A1 (en) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
FI3774791T3 (en) 2018-03-30 2023-03-21 Incyte Corp Heterocyclic compounds as immunomodulators
BR112020022936A2 (en) 2018-05-11 2021-02-02 Incyte Corporation tetrahydro-imidazo [4,5-c] pyridine derivatives as pd-l1 immunomodulators
JP2022500452A (en) * 2018-09-13 2022-01-04 エイリオン セラピューティクス， インコーポレイテッド Use of plasminogen activator inhibitor 1 (PAI-1) inhibitor (inhibitor)
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN111825605B (en) * 2019-04-19 2023-03-31 中国科学院上海药物研究所 Aryl ketone amide compound and preparation method and application thereof
TW202112767A (en) 2019-06-17 2021-04-01 美商佩特拉製藥公司 Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
JP7559059B2 (en) 2019-09-30 2024-10-01 インサイト・コーポレイション Pyrido[3,2-D]pyrimidine compounds as immunomodulators - Patents.com
AU2020380395A1 (en) * 2019-11-05 2022-05-26 Dermira, Inc. MrgprX2 antagonists for the treatment of inflammatory disorders
MX2022005651A (en) 2019-11-11 2022-07-27 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor.
TW202128675A (en) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 Substituted tetrahydrofurans as modulators of sodium channels
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
TW202233615A (en) 2020-11-06 2022-09-01 美商英塞特公司 Crystalline form of a pd-1/pd-l1 inhibitor
KR20230117573A (en) 2020-11-06 2023-08-08 인사이트 코포레이션 Methods for preparing PD-1 and PD-L1 inhibitors and salts and crystalline forms thereof
CN113209112B (en) * 2021-02-06 2021-12-24 广州市朝利良生物科技有限公司 Novel coronavirus resistant medicine based on ACE2 and S protein binding target and application thereof
PE20241335A1 (en) 2021-06-04 2024-07-03 Vertex Pharma N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS
WO2024059220A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
CN118496159B (en) * 2024-07-18 2024-09-24 广州医科大学附属市八医院 Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092576A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors

Also Published As

Publication number Publication date
WO2007146712A2 (en) 2007-12-21
CL2007001670A1 (en) 2008-01-18
EP2035005A2 (en) 2009-03-18
EP2035005A4 (en) 2011-07-06
AR061273A1 (en) 2008-08-13
WO2007146712A3 (en) 2008-11-27
CA2691214A1 (en) 2007-12-21
AU2007257959A1 (en) 2007-12-21
TW200814998A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
PE20080935A1 (en) THERAPY USING CYTOKINE INHIBITORS
MX2010003865A (en) Aryl amides useful as inhibitors of voltage-gated sodium channels.
EA200900155A1 (en) MODULATORS OF PHARMACOKINETIC PROPERTIES OF MEDICINES
MX2010003864A (en) Amides useful as inhibitors of voltage-gated sodium channels.
NO20092637L (en) Methods of treatment
EA200700118A1 (en) AMIDOCIOUSNESS AND THEIR APPLICATION AS MEDICINES
NO20064852L (en) Azaindoles useful as inhibitors of yak and other protein kinases
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
EA200900874A1 (en) APPLICATION OF ERYTHROPOIETHIN IN LOW DOSAGE FOR STIMULATION OF ENDOTHELIAL CELLS PRECONDENTS, AND ALSO FOR REGENERATION OF ORGANS AND SLOWING PROGRESSION OF DAMAGES OF FINAL ORGANS
EA200700074A1 (en) A METHOD FOR INCREASING THE RATE OF HEALING DAMAGE (OPTIONS), A DEVICE FOR DELIVERY OF HYDROGEN PEROXIDE AND A COMPOSITION FOR THE TREATMENT OF INJURIES IN MAMMALS
MX2007005434A (en) Nanoparticulate compositions of tubulin inhibitor.
NO20052888L (en) Diamin triazoles useful as inhibitors of protein kinases
DK1611088T3 (en) Hydroxymates as therapeutic agents
EA200870380A1 (en) AMINOTETRAHYDROPYRANE AS DIPEPTIDYLPEPTIDASE-VI INHIBITORS FOR TREATMENT OR PREVENTION OF DIABETES
MX2010003866A (en) Heteroaryl amides useful as inhibitors of voltage-gated sodium channels.
MA33806B1 (en) INHIBITORS OF HEPATITIS C VIRUS
NO20063368L (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EA200970915A1 (en) METHODS OF TREATMENT USING GLYCOPYGLATED G-CSF
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
NO20090157L (en) Ten pyrimidines useful as modulators of ion channels
ATE484501T1 (en) BENZIMIDAZOLES USABLE AS PROTEIN KINASE INHIBITORS
ATE432279T1 (en) TRICYCLIC DELTA OPIOID MODULATORS
EA201170351A1 (en) METHODS OF TREATING NEUROPATHIC PAIN
MY148893A (en) Combination of an hdac inhibitor and an antimetabolite
EA201071043A1 (en) NEW DERIVATIVES 1-BENZYL-3-HYDROXYMETHYLINDASOL AND THEIR APPLICATION IN THE TREATMENT OF DISEASES CAUSED BY EXPRESSION OF MCP-1 AND CX3CR1

Legal Events

Date Code Title Description
FX Voluntary withdrawal